Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progress Toward <italic>In Vivo</italic> Use of siRNAs-II</title><author><name sortKey="Rettig, Garrett R" sort="Rettig, Garrett R" uniqKey="Rettig G" first="Garrett R" last="Rettig">Garrett R. Rettig</name><affiliation><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>, Coralville, Iowa,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Behlke, Mark A" sort="Behlke, Mark A" uniqKey="Behlke M" first="Mark A" last="Behlke">Mark A. Behlke</name><affiliation><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>, Coralville, Iowa,<country>USA</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22186795</idno><idno type="pmc">3293614</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293614</idno><idno type="RBID">PMC:3293614</idno><idno type="doi">10.1038/mt.2011.263</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000008</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000008</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Progress Toward <italic>In Vivo</italic> Use of siRNAs-II</title><author><name sortKey="Rettig, Garrett R" sort="Rettig, Garrett R" uniqKey="Rettig G" first="Garrett R" last="Rettig">Garrett R. Rettig</name><affiliation><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>, Coralville, Iowa,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Behlke, Mark A" sort="Behlke, Mark A" uniqKey="Behlke M" first="Mark A" last="Behlke">Mark A. Behlke</name><affiliation><nlm:aff id="aff1"><institution>Integrated DNA Technologies, Inc.</institution>, Coralville, Iowa,<country>USA</country></nlm:aff></affiliation></author></analytic><series><title level="j">Molecular Therapy</title><idno type="ISSN">1525-0016</idno><idno type="eISSN">1525-0024</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>RNA interference (RNAi) has been extensively employed for <italic>in vivo</italic> research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of <italic>in vivo</italic> RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact <italic>in vivo</italic> use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther</journal-id><journal-title-group><journal-title>Molecular Therapy</journal-title></journal-title-group><issn pub-type="ppub">1525-0016</issn><issn pub-type="epub">1525-0024</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22186795</article-id><article-id pub-id-type="pmc">3293614</article-id><article-id pub-id-type="pii">mt2011263</article-id><article-id pub-id-type="doi">10.1038/mt.2011.263</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Progress Toward <italic>In Vivo</italic> Use of siRNAs-II</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rettig</surname><given-names>Garrett R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Behlke</surname><given-names>Mark A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Integrated DNA Technologies, Inc.</institution>, Coralville, Iowa,<country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Integrated DNA Technologies, Inc., 1710 Commercial Park, Coralville, Iowa 52241, USA. E-mail: <email>mbehlke@idtdna.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>03</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2011</year></pub-date><volume>20</volume><issue>3</issue><fpage>483</fpage><lpage>512</lpage><history><date date-type="received"><day>02</day><month>09</month><year>2011</year></date><date date-type="accepted"><day>08</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2012 The American Society of Gene & Cell Therapy</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>The American Society of Gene & Cell Therapy</copyright-holder></permissions><abstract><p>RNA interference (RNAi) has been extensively employed for <italic>in vivo</italic> research since its use was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it is now routinely possible to obtain reagents that suppress expression of any gene desired. At the same time, increased understanding of the molecular basis of unwanted side effects has led to the development of chemical modification strategies that mitigate these concerns. Delivery remains the single greatest hurdle to widespread adoption of <italic>in vivo</italic> RNAi methods. However, exciting advances have been made and new delivery systems under development may help to overcome these barriers. This review discusses advances in RNAi biochemistry and biology that impact <italic>in vivo</italic> use and provides an overview of select publications that demonstrate interesting applications of these principles. Emphasis is placed on work with synthetic, small interfering RNAs (siRNAs) published since the first installment of this review which appeared in 2006.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000008 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000008 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |